• Je něco špatně v tomto záznamu ?

Adjustment of serum HE4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer

J. Chovanec, I. Selingerova, K. Greplova, SL. Antonsen, M. Nalezinska, C. Høgdall, E. Høgdall, E. Søgaard-Andersen, KM. Jochumsen, P. Fabian, D. Valik, L. Zdrazilova-Dubska,

. 2017 ; 8 (64) : 108213-108222. [pub] 20171121

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18010114

Background: We investigated the efficacy of circulating biomarkers together with histological grade and age to predict deep myometrial invasion (dMI) in endometrial cancer patients. Methods: HE4ren was developed adjusting HE4 serum levels towards decreased glomerular filtration rate as quantified by the eGFR-EPI formula. Preoperative HE4, HE4ren, CA125, age, and grade were evaluated in the context of perioperative depth of myometrial invasion in endometrial cancer (EC) patients. Continuous and categorized models were developed by binary logistic regression for any-grade and for G1-or-G2 patients based on single-institution data from 120 EC patients and validated against multicentric data from 379 EC patients. Results: In non-cancer individuals, serum HE4 levels increase log-linearly with reduced glomerular filtration of eGFR ≤ 90 ml/min/1.73 m2. HE4ren, adjusting HE4 serum levels to decreased eGFR, was calculated as follows: HE4ren = exp[ln(HE4) + 2.182 × (eGFR-90) × 10-2]. Serum HE4 but not HE4ren is correlated with age. Model with continuous HE4ren, age, and grade predicted dMI in G1-or-G2 EC patients with AUC = 0.833 and AUC = 0.715, respectively, in two validation sets. In a simplified categorical model for G1-or-G2 patients, risk factors were determined as grade 2, HE4ren ≥ 45 pmol/l, CA125 ≥ 35 U/ml, and age ≥ 60. Cumulation of weighted risk factors enabled classification of EC patients to low-risk or high-risk for dMI. Conclusions: We have introduced the HE4ren formula, adjusting serum HE4 levels to reduced eGFR that enables quantification of time-dependent changes in HE4 production and elimination irrespective of age and renal function in women. Utilizing HE4ren improves performance of biomarker-based models for prediction of dMI in endometrial cancer patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010114
003      
CZ-PrNML
005      
20180405103544.0
007      
ta
008      
180404s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.22599 $2 doi
035    __
$a (PubMed)29296235
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Chovanec, Josef $u Clinic of Surgical Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic. Regional Centre of Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
245    10
$a Adjustment of serum HE4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer / $c J. Chovanec, I. Selingerova, K. Greplova, SL. Antonsen, M. Nalezinska, C. Høgdall, E. Høgdall, E. Søgaard-Andersen, KM. Jochumsen, P. Fabian, D. Valik, L. Zdrazilova-Dubska,
520    9_
$a Background: We investigated the efficacy of circulating biomarkers together with histological grade and age to predict deep myometrial invasion (dMI) in endometrial cancer patients. Methods: HE4ren was developed adjusting HE4 serum levels towards decreased glomerular filtration rate as quantified by the eGFR-EPI formula. Preoperative HE4, HE4ren, CA125, age, and grade were evaluated in the context of perioperative depth of myometrial invasion in endometrial cancer (EC) patients. Continuous and categorized models were developed by binary logistic regression for any-grade and for G1-or-G2 patients based on single-institution data from 120 EC patients and validated against multicentric data from 379 EC patients. Results: In non-cancer individuals, serum HE4 levels increase log-linearly with reduced glomerular filtration of eGFR ≤ 90 ml/min/1.73 m2. HE4ren, adjusting HE4 serum levels to decreased eGFR, was calculated as follows: HE4ren = exp[ln(HE4) + 2.182 × (eGFR-90) × 10-2]. Serum HE4 but not HE4ren is correlated with age. Model with continuous HE4ren, age, and grade predicted dMI in G1-or-G2 EC patients with AUC = 0.833 and AUC = 0.715, respectively, in two validation sets. In a simplified categorical model for G1-or-G2 patients, risk factors were determined as grade 2, HE4ren ≥ 45 pmol/l, CA125 ≥ 35 U/ml, and age ≥ 60. Cumulation of weighted risk factors enabled classification of EC patients to low-risk or high-risk for dMI. Conclusions: We have introduced the HE4ren formula, adjusting serum HE4 levels to reduced eGFR that enables quantification of time-dependent changes in HE4 production and elimination irrespective of age and renal function in women. Utilizing HE4ren improves performance of biomarker-based models for prediction of dMI in endometrial cancer patients.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Selingerova, Iveta $u Regional Centre of Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Greplova, Kristina $u Regional Centre of Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic. Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Antonsen, Sofie Leisby $u Gynecologic Clinic, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
700    1_
$a Nalezinska, Monika $u Clinic of Surgical Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Høgdall, Claus $u Gynecologic Clinic, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
700    1_
$a Høgdall, Estrid $u Department of Pathology, Danish Cancer Biobank, Herlev University Hospital, Herlev, Denmark.
700    1_
$a Søgaard-Andersen, Erik $u Department of Gynecology and Obstetrics, Aalborg University Hospital, Aalborg, Denmark.
700    1_
$a Jochumsen, Kirsten M $u Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark.
700    1_
$a Fabian, Pavel $u Department of Oncological Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Valik, Dalibor $u Regional Centre of Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic. Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Zdrazilova-Dubska, Lenka $u Regional Centre of Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic. Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 8, č. 64 (2017), s. 108213-108222
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29296235 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180405103625 $b ABA008
999    __
$a ind $b bmc $g 1287599 $s 1006926
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 8 $c 64 $d 108213-108222 $e 20171121 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Možnosti archivace